Genelux (NASDAQ:GNLX) Director John Smither Sells 12,000 Shares

Genelux Corporation (NASDAQ:GNLX) Director John Smither sold 12,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total value of $34,920.00. Following the sale, the director owned 91,403 shares in the company, valued at $265,982.73. The trade was a 11.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Genelux Stock Performance

Shares of NASDAQ:GNLX opened at $2.99 on Friday. The business has a fifty day moving average of $2.89 and a 200-day moving average of $2.93. Genelux Corporation has a twelve month low of $2.29 and a twelve month high of $8.53. The firm has a market cap of $134.07 million, a PE ratio of -3.52 and a beta of 0.58.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, analysts anticipate that Genelux Corporation will post -0.8 EPS for the current fiscal year.

Institutional Trading of Genelux

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GNLX. Goldman Sachs Group Inc. boosted its stake in shares of Genelux by 451.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 183,807 shares of the company’s stock valued at $801,000 after purchasing an additional 150,463 shares during the last quarter. 683 Capital Management LLC bought a new stake in shares of Genelux during the fourth quarter worth approximately $572,000. Marshall Wace LLP raised its stake in shares of Genelux by 312.3% during the fourth quarter. Marshall Wace LLP now owns 139,148 shares of the company’s stock worth $607,000 after buying an additional 105,402 shares during the last quarter. Millennium Management LLC acquired a new position in Genelux in the fourth quarter valued at approximately $455,000. Finally, Osaic Holdings Inc. lifted its holdings in Genelux by 1,911.4% in the second quarter. Osaic Holdings Inc. now owns 105,016 shares of the company’s stock valued at $301,000 after buying an additional 99,795 shares during the period. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Wall Street Zen cut shares of Genelux from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a research report on Tuesday, April 21st. Finally, Benchmark dropped their price objective on shares of Genelux from $23.00 to $20.00 and set a “speculative buy” rating for the company in a research report on Friday, March 20th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.